{"altmetric_id":3298508,"counts":{"readers":{"mendeley":31,"citeulike":0,"connotea":0},"total":{"posts_count":2},"wikipedia":{"unique_users_count":2,"unique_users":["en:1624274","en:9134216"],"posts_count":2}},"citation":{"abstract":"Pharmacological modulation of complement activation recently has been postulated as a therapeutic target in the treatment of neurological injury. We hypothesized that pexelizumab, a humanized scFv monoclonal antibody directed against the C5 complement component, would limit deficits in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.","abstract_source":"pubmed","altmetric_jid":"4f6fa5eb3cf058f610005cfc","authors":["Joseph P. Mathew","Stanton K. Shernan","William D. White","Jane C.K. Fitch","John C. Chen","Leonard Bell","Mark F. Newman","Mathew JP","Shernan SK","White WD","Fitch JC","Chen JC","Bell L","Newman MF","J. P. Mathew"],"doi":"10.1161\/01.str.0000141938.00524.83","endpage":"2339","first_seen_on":"2015-02-04T05:39:38+00:00","issns":["1524-4628","0039-2499"],"issue":"10","journal":"Stroke","last_mentioned_on":1270734458,"links":["http:\/\/dx.doi.org\/10.1161\/01.STR.0000141938.00524.83","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15331798"],"pdf_url":"http:\/\/stroke.ahajournals.org\/content\/35\/10\/2335.full.pdf","pmid":"15331798","pubdate":"2004-10-14T23:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Cardiovascular Medicine And Haematology","scheme":"era"},{"name":"Neurosciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"2335","subjects":["brain"],"title":"Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.","type":"article","uri":"http:\/\/stroke.ahajournals.org\/cgi\/doi\/10.1161\/01.STR.0000141938.00524.83","volume":"35","mendeley_url":"http:\/\/www.mendeley.com\/research\/preliminary-report-effects-complement-suppression-pexelizumab-neurocognitive-decline-after-coronary"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":3631265,"mean":4.9266893682253,"rank":816079,"this_scored_higher_than_pct":63,"this_scored_higher_than":2292977,"rank_type":"exact","sample_size":3631265,"percentile":63},"similar_age_3m":{"total_number_of_other_articles":94409,"mean":8.1047755063133,"rank":24512,"this_scored_higher_than_pct":72,"this_scored_higher_than":68805,"rank_type":"exact","sample_size":94409,"percentile":72},"this_journal":{"total_number_of_other_articles":3689,"mean":5.4528904555314,"rank":1076,"this_scored_higher_than_pct":62,"this_scored_higher_than":2316,"rank_type":"exact","sample_size":3689,"percentile":62},"similar_age_this_journal_3m":{"total_number_of_other_articles":43,"mean":4.8253333333333,"rank":18,"this_scored_higher_than_pct":55,"this_scored_higher_than":24,"rank_type":"exact","sample_size":43,"percentile":55}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":7,"Student  > Doctoral Student":3,"Student  > Ph. D. Student":5,"Student  > Postgraduate":2,"Student  > Master":7,"Other":2,"Student  > Bachelor":2,"Professor":1},"by_discipline":{"Medicine and Dentistry":20,"Psychology":3,"Agricultural and Biological Sciences":3,"Nursing and Health Professions":1,"Biochemistry, Genetics and Molecular Biology":2,"Mathematics":1,"Unspecified":1}}},"geo":{"mendeley":{"GB":1,"DE":1}}},"posts":{"wikipedia":[{"title":"Single-chain variable fragment","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=354744913#altmetric_citation_4","license":"public","citation_ids":[3298508],"posted_on":"2010-04-08T13:47:38+00:00","summary":"A single-chain variable fragment (scFv) is not actually a fragment of an antibody, but instead is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of immunoglobulins, connected with a short linker peptide of ten to about 25","page_url":"http:\/\/en.wikipedia.org\/?curid=1624274","wiki_lang":"en","author":{"name":"Anypodetos","url":"http:\/\/en.wikipedia.org\/wiki\/User:Anypodetos"}},{"title":"Pexelizumab","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=353961806#altmetric_citation_1","license":"public","citation_ids":[3298508],"posted_on":"2010-04-04T20:02:19+00:00","summary":"Alexion, the developer of pexelizumab stopped development due to disappointing phase 3 results indicating the heart-attack drug is no better than placebo.","page_url":"http:\/\/en.wikipedia.org\/?curid=9134216","wiki_lang":"en","author":{"name":"Anypodetos","url":"http:\/\/en.wikipedia.org\/wiki\/User:Anypodetos"}}]}}